Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is an international multicenter open label randomized phase III trial in children with
relapsed and refractory acute myeloid leukemia (AML) such a disease. The main purpose of this
study is to determine the efficacy and toxicity of liposomal daunorubicin when added to
fludarabine, ara-C and G-CSF(FLAG) in children with relapsed and refractory AML.
Phase:
Phase 3
Details
Lead Sponsor:
Dutch Childhood Oncology Group
Collaborators:
International BFM Study Group St. Jude Children's Research Hospital